Brief: Helix Biopharma Corp. And Moffitt Cancer Center Extend Collaboration On Immunotherapy, Including Study Of L-Dos47 With Pd-1/Pd-L1 Inhibitors
10/10/2018 12:39
Oct 10 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. AND MOFFITT CANCER CENTER EXTEND
COLLABORATION ON IMMUNOTHERAPY, INCLUDING STUDY OF L-DOS47 WITH
PD-1/PD-L1 INHIBITORS
* HELIX BIOPHARMA CORP - IT HAS EXTENDED ITS COLLABORATION
AGREEMENT WITH MOFFITT CANCER CENTER FOR AN ADDITIONAL YEAR
Source text for Eikon: ID:nGNX3Yyp8M
Further company coverage: HBP.TO
((Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020